New auto-injector technology that is user-friendly and capable of delivering high viscosity drugs may be the next big thing for pharma and biotech companies pushing further into niche biologics and biosimilars.
Following a “significant increase in demand” GVK Biosciences has partnered with Quantitative Solutions (QS) to develop and market clinical trial outcome databases, which they believe can improve drug development.
The merger between Mitsubishi Chemical Holding's pharmaceutical
unit and Tanabe Seiyaku has been completed and the new entity is
looking to expand its presence outside Japan and create a more
efficient R&D and manufacturing...
The UK's drug reimbursement watchdog has given the green light for
the first time to a treatment specifically for multiple sclerosis
(MS) and also gave the thumbs up to two arthritis drugs, all of
which are biologics.
Asterand is to make available novel research materials to be used
in the investigation of rheumatoid arthritis, osteoarthritis,
cancer and other diseases making available a range of cell material
that is currently difficult to obtain.
Biogen has revealed details of a potential new pathway in
rheumatoid arthritis (RA) that could provide unique insights into
the disease process and eventually a new approach to developing RA
In an incident Roxane Laboratories warns could have
life-threatening consequences, a manufacturing lot of azathioprine
tablets has been recalled in the US and Puerto Rico following the
discovery of methotrexate tablets in one of its...
EntreMed has produced hard data demonstrating antiangiogenic
activity of its lead compound against the devastating effects of
rheumatoid arthritis (RA). The results pave the way to developing
therapeutics for the cancer and inflammatory...
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.
Rigel has completed the Phase I stage of its drug interaction study
in patients with rheumatoid arthritis. The oral syk kinase
inhibitor could be an improvement over current treatment options,
which have side effects that include...
Scientists exploring inflammation in rheumatoid arthritis have made
an unexpected discovery that may lead to new drug treatments to
ease the pain and discomfort endured by 66 million (nearly 1 in 3
adults) US citizens in 2005.
Lonza has scored a manufacturing contract to help Bristol
Myers-Squibb (BMS) meet anticipated demand of its newly approved
drug that will offer a new treatment option for rheumatoid
arthritis, a disease that afflicts more than two...
Domantis has announced an alliance with pharma giants Bristol-Myers
Squibb to develop human Domain Antibody (dAb) products, a novel
approach to address therapeutic targets involved in T-cell
Pfizer and Incyte have entered a collaborative research and license
agreement for the development and commercialisation of CCR2
antagonists - an emerging class of drug that aims to serve an unmet
need in the treatment of rheumatoid...
Scientists have synthesised a lab-made version of a human protein,
which alleviates symptoms of both acute and chronic arthritis. The
study opens new research avenues to better understand and develop
drug treatments for rheumatoid...
An antibody drug candidate to treat autoimmune diseases has been
exclusively in-licensed by KaloBios Pharmaceuticals who hope to
develop this compound into a practicable treatment for rheumatoid
arthritis (RA), which currently...
A rheumatoid arthritis drug developed by Franco-German company
Aventis has been linked to the deaths of five patients in Japan,
prompting the company to warn against prescribing the drug to
people with respiratory problems.
Lonza Biotec is to manufacture PEGylated antibody fragment-based
drugs for Celltech under the terms of a new agreement between the
two companies. The two companies have also reached an agreement on
a prior deal relating to Celltech's...